Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Data from proteome profiling in breast cancer cells with less ZNF143 suggest a role of NAD(P)H quinone dehydrogenase 1(NQO1) for p53 stability.
|
30935019 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we focus our studies on the specific NQO1 bioactivatable drug, ß-lapachone, which is in several Phase I clinical trials to treat human non-small cell lung, pancreatic and breast cancers.
|
30098460 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
NQO1 is Required for β-Lapachone-Mediated Downregulation of Breast-Cancer Stem-Cell Activity.
|
30513573 |
2018 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings have suggested that the NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism combination with smoking significantly confer susceptibility to BC.
|
28589969 |
2017 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings have suggested that the NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism combination with smoking significantly confer susceptibility to BC.
|
28589969 |
2017 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, two breast cancer cell lines, MDA-MB-231 and MCF-7, were chosen for analysis as they are characterized by different NQO1 protein levels.
|
28006669 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
RGD |
Dietary lipids differentially modulate the initiation of experimental breast carcinogenesis through their influence on hepatic xenobiotic metabolism and DNA damage in the mammary gland.
|
28264783 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results demonstrated that NQO1 could be a useful prognostic biomarker for patients with breast cancer, and its bioactivatable drug, β-lapachone represented a promising new development and an effective strategy for indicating the progression of NQO1-positive breast cancers.
|
28578385 |
2017 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, NRF2-NQO1 pathway plays an essential role in mediating the activity of MXP and its active components, at least in part; some beneficial effects of MXP may be applicable to breast cancer chemoprevention.
|
29214656 |
2017 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
More specifically, higher levels of NQO1 mRNA strongly predict patient relapse in high-risk ER(+) breast cancer patients receiving endocrine therapy (mostly tamoxifen; H.R.> 2.15; p = 0.007).
|
28411284 |
2017 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Generalized multi-analytical (GMDR) approach was used to determine the influence of the combination of variants of genes encoding phase 0 (SLC22A16); phase I (CYP450, NQO1); phase II (GSTs, MTHFR, UGT2B15); and phase III (ABCB1) DMEs along with confounding factors on the response and toxicity of chemotherapeutic drugs in breast cancer patients.
|
26506825 |
2016 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The present study shows a strong association between NQO1 C609T polymorphism with the breast cancer risk in the north Indian breast cancer patients so that possible use as a risk factor should be further explored.
|
27039751 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because NQO1 is frequently modified in tumors at genomic and transcriptomic levels, the impact of NQO1 modulation on breast cancer cell sensitivity places NQO1 as a potential link between cancer redox alterations and resistance to chemotherapy.
|
26687450 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
NQO1 knockdown in human colorectal and breast cancer cell lines suppresses HIF-1 signalling and tumour growth.
|
27966538 |
2016 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, the NQO1 187Ser carriers were associated with an increased bladder cancer risk (homozygous: OR = 1.43, 95% CI = 1.08-1.90; recessive: OR = 1.33, 95% CI = 1.03-1.72; dominant: OR = 1.19, 95% CI = 1.04-1.37, and allele comparing: OR = 1.18, 95% CI = 1.06-1.33).
|
25602258 |
2015 |
Malignant neoplasm of urinary bladder
|
0.600 |
Biomarker
|
disease |
BEFREE |
quinone oxidoreductase I (NQO1) and superoxide dismutase 2 (SOD2), and urinary bladder cancer risk among male agricultural workers in Egypt.
|
24219772 |
2015 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, the NQO1 187Ser carriers were associated with an increased bladder cancer risk (homozygous: OR = 1.43, 95% CI = 1.08-1.90; recessive: OR = 1.33, 95% CI = 1.03-1.72; dominant: OR = 1.19, 95% CI = 1.04-1.37, and allele comparing: OR = 1.18, 95% CI = 1.06-1.33).
|
25602258 |
2015 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The study provides useful information for prediction of clinical outcomes in breast cancer patients in terms of NQO1 609C>T by evaluating its association with chemotherapy-induced toxicity.
|
26014925 |
2015 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, a meta-analysis of the Exon 6 (C > T) polymorphism and BC risk showed that the variant of NQO1 Exon 6 genotypes was associated with an overall increased risk of BC, which was consistent with the results of the present study.
|
24676794 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The highest odds for having bladder cancer following SH infection were observed among individuals with the CC genotypes for both NQO1 and SOD2 (OR [CI 95%] = 4.41 [2.32-8.38]).
|
24035474 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared with study participants carrying the C/C genotype of NQO1 gene, those with C/T and T/T genotypes had a significantly increased BC risk of 1.8 (95% CI = 1.1-2.9).
|
24315573 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, a meta-analysis of the Exon 6 (C > T) polymorphism and BC risk showed that the variant of NQO1 Exon 6 genotypes was associated with an overall increased risk of BC, which was consistent with the results of the present study.
|
24676794 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The highest odds for having bladder cancer following SH infection were observed among individuals with the CC genotypes for both NQO1 and SOD2 (OR [CI 95%] = 4.41 [2.32-8.38]).
|
24035474 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared with study participants carrying the C/C genotype of NQO1 gene, those with C/T and T/T genotypes had a significantly increased BC risk of 1.8 (95% CI = 1.1-2.9).
|
24315573 |
2014 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We did not observe a significant association between NQO1 Pro187Ser polymorphism and breast cancer risk when all studies were pooled into the meta-analysis.
|
24884893 |
2014 |